Double Proteolysis for N- and O-glycan Analysis of Fc-fusion Protein Etanercept
Introduction. Highly glycosylated proteins are the most abundant class of modern biopharmaceuticals. A majority of such therapeuticals produced by Russian biopharmaceutical companies is biosimilars. The foundation of biosimilar manufacturing is analytical assessment of structure equivalence to an or...
Saved in:
Main Authors: | V. G. Varzieva, N. V. Mesonzhnik, A. О. Belushenko, N. L. Bochkareva, S. А. Appolonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2023-02-01
|
Series: | Разработка и регистрация лекарственных средств |
Subjects: | |
Online Access: | https://www.pharmjournal.ru/jour/article/view/1440 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of the biosimilar etanercept in the treatment of patients with rheumatoid arthritis and spondyloarthritis
by: B. G. Issayeva, et al.
Published: (2024-10-01) -
Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations
by: T. M. Bzarova, et al.
Published: (2016-01-01) -
Raider of the lost N-glycans – Localizing rare and frequently overlooked IgG N-glycans with sulfation or bisecting LacNAc
by: Robert Burock, et al.
Published: (2025-07-01) -
Immunoglobulin A carries sulfated and O-acetylated N-glycans primarily at the tailpiece site – strategies for site-specific N-glycan identification
by: Frania J. Zuniga-Banuelos, et al.
Published: (2025-08-01) -
Experience of etanercept treatment in juvenile ankylosing spondyloarthritis
by: A. N. Fetisova, et al.
Published: (2013-03-01)